trial

A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

NCTId NCT02469155
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 696 (actual)
Sponsored by Intra-Cellular Therapies, Inc.
Primary completion 2016-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
696 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-06
Primary completion
2016-08
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Lumateperone (Caplyta)Risperidone

Sponsors

Intra-Cellular Therapies, Inc.Lead Sponsor

Investigators

1
Kimberly Vanover, Ph.D.Study Director

Sites

11 total
Little Rock, United StatesSpringdale, United StatesCulver City, United StatesLemon Grove, United StatesLong Beach, United StatesSan Diego, United StatesNorth Miami, United StatesBerlin, United StatesMarlton, United StatesAustin, United StatesDallas, United States

Linked catalysts

1
A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatmen — primary completion2016-08

Facts & assertions

4 sourced
Enrollment
696
Phase
PHASE3
Primary Completion Date
2016-08
Status
COMPLETED
relationships
The graph out of here
drug
Lumateperone (Caplyta)
drug
Risperidone
drug
lead_sponsor
Intra-Cellular Therapies, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Kimberly Vanover, Ph.D.
person